Multiple pathways to tumor immunity and concomitant autoimmunity.

Area of Science:

• Immunology
• Cancer Research
• Autoimmunity

Background:

• The immune system possesses T cells and B cells capable of recognizing cancer cells, including those expressing self or altered self-antigens.
• Inducing immune responses against self-antigens in cancer is challenging.
• Tumor immunity can involve diverse mechanisms in both priming and effector phases.

Purpose of the Study:

• To present strategies for eliciting immunity against self-antigens in poorly immunogenic tumors using altered self-antigens.
• To elucidate the diverse mechanisms of cancer immunity.
• To explore the relationship between tumor immunity and autoimmunity.

Main Methods:

• Utilizing altered self-antigens to prime immune responses against self-antigens in tumor models.
• Analyzing the roles of CD4+ T cells in immune priming.
• Investigating effector mechanisms including cytotoxic T cells, Fc receptor-activating macrophages, and killer domain molecules.

Main Results:

• Strategies using altered self-antigens can elicit immunity against self-antigens in challenging tumor models.
• Diverse immune strategies are employed in both immunization and effector phases of cancer immunity.
• CD4+ T cells are generally required for immunization, but not always.
• Effector mechanisms include cytotoxic T cells, macrophages, and killer domain molecules.
• Tumor immunity and autoimmunity can be uncoupled, despite sharing similar mechanisms.

Conclusions:

• Novel strategies employing altered self-antigens can overcome challenges in priming anti-cancer immunity.
• The immune system exhibits remarkable diversity in mediating cancer immunity.
• Understanding the mechanisms of tumor immunity can inform strategies for active cancer immunization while managing potential autoimmunity.